Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Yoshikazu Inoue et al.|The Lancet Respiratory Medicine|2020Cited by 558
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialJürgen Behr, Antje Prasse, Michael Kreuter et al.|The Lancet Respiratory Medicine|2021Cited by 523